UEG Week 2025: Relive the Highlights

From groundbreaking research to expert debate — experience it all again on demand. Recordings and posters now available on gutflix.eu

Explore your recommendations now!

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Functional abdominal pain: Paediatric and adult gastroenterologist

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Not sure what you can access? Learn more about account types.

Functional abdominal pain: Paediatric and adult gastroenterologist

Giovanni Barbara 1, Jernej Dolinsek 2

1 University of Bologna, Bologna, Italy

2 UMC Maribor, Maribor, Slovenia

Event

UEG Week Berlin 2025

Session

When adult gastroenterologist meets paediatrician: Focus on reflux, constipation and chronic pain

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

A MULTICENTER RETROSPECTIVE STUDY OF INFLUENTIAL FACTORS ON STENOSIS AFTER MODERATE RESECTION OF CIRCUMFERENCE IN ESOPHAGEAL ENDOSCOPIC SUBMUCOSAL DISSECTION

Not sure what you can access? Learn more about account types.

Introduction

Endoscopic submucosal dissection (ESD) is an effective treatment for superficial esophageal cancer, but postoperative stenosis remains a significant concern. Particularly, probability of the stenosis is less investigated in cases with a 50%-75% circumferential mucosal defect.

Aims & Methods

This study aimed to identify influential factors for postoperative stenosis after the moderate circumferential resection in esophageal ESD. This multi-center retrospective observational study analyzed data from 513 patients across 19 institutions who underwent esophageal ESD from April 2018 to March 2022 and showed 50% to 75% of the circumferential mucosal defect. We firstly overviewed the current status on the postoperative stenosis, the steroid use, and postoperative adverse events in these patients. Subsequently, we identified influential factors for postoperative stenosis. Patients were categorized into stenosis and no stenosis groups, and univariate and multivariate analyses were performed for each parameter. We further investigated influential factors of stenosis in two cohorts: steroid and no steroid groups. Finally, the parameters were compared between the steroid and no steroid groups to assess the tendency of the steroid use in general practice.

Results

Postoperative stenosis was observed in 28 cases (5%). Univariate analysis comparing the stenosis group (n = 28) and no stenosis group (n = 485) revealed significant differences in the prior endoscopic treatment near the lesion (p = 0.02), cervical esophageal location (p = 0.04), defect circumference (p =0.01), and procedure duration (p = 0.02). There was no significant difference in the steroid use between two groups. Multivariate analyses identified history of prior endoscopic treatment close to the lesion (p = 0.01, odds ratio [OR], 5.10), cervical esophageal lesions (p = 0.03, OR, 3.97), large circumferential defect (p <0.01, OR, 3.78), and longer procedure duration (p <0.01, OR, 3.83) as independent risk factors for stenosis formation. Among the steroid group, significant associations of the postoperative stenosis were revealed with the prior endoscopic treatment near the lesion (p = 0.02), cervical esophageal location (p = 0.04), and >5/8 of defect circumference (p = 0.02). In the no steroid group, only the procedure duration (p = 0.01) showed a significant difference between the stenosis and non-stenosis groups. Comparison between the steroid (n = 223) and no steroid groups (n = 290) revealed significant differences in the prior endoscopic treatment near the lesion (p <0.01), cervical esophageal lesions (p <0.01), and resected specimen dimensions (p <0.01). The stenosis rates were 7% in the steroid group and 4% in the no steroid group, without a significant difference. No significant difference in adverse events was observed between the two groups.

Conclusion

In esophageal ESD with a 50%-75% circumferential mucosal defect, the steroid was used in over 40% of patients, and postoperative stenosis still occurred in 5%. Because wider circumference, location of the cervical esophagus, prior endoscopic treatment close to the lesion, and prolonged operative time were identified as independent risk factors on the stenosis, steroid therapy should be preferred in these cases. Particularly, lesions with a history of endoscopic treatment, on cervical esophagus, and with >5/8 of defect circumference should require more aggressive countermeasures than currently applied.

A MULTICENTER RETROSPECTIVE STUDY OF INFLUENTIAL FACTORS ON STENOSIS AFTER MODERATE RESECTION OF CIRCUMFERENCE IN ESOPHAGEAL ENDOSCOPIC SUBMUCOSAL DISSECTION

Akira Dobashi 1, Tsugumi Habu 2, Osamu Goto 3, Toshiyuki Yoshio 4, Waku Hatta 5, Noboru Kawata 6, Atsushi Goto 7, Unknown Unknown 8, Yugo Iwaya 9, Tetsuya Tatsuta 10, Takuto Hikichi 11, Jun Nakamura 11, Shinjiro Yamaguchi 12, Takashi Ohta 12, Yohei Furumoto 13, Tsutomu Nishida 14, Masashi Yamamoto 14, Mikitaka Iguchi 15, Tatsuo Yachida 16, Hiroko Nebiki 17, Tomoaki Yamasaki 17, Toshiaki Narasaka 18, Eriko Koizumi 2, Yosuke Tsuji 19, Kazuki Sumiyama 1, Mitsuhiro Fujishiro 19

1 The Jikei University School of Medicine, Tokyo, Japan

2 Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan

3 Nippon Medical School, Tokyo, Japan

4 Cancer Institute Hospital, Japanese Foundation for Cancer Reserch, Tokyo, Japan

5 Tohoku University, Graduate School of Medicine, Sendai, Japan

6 Shizuoka Cancer Center, Shizuoka, Japan

7 Yamaguchi University Graduate School of Medicine, Ube, Japan

8 Tonan Hospital, Hokkaido, Japan

9 Shinshu University School of Medicine, Matsumoto, Japan

10 Hirosaki University Hospital, Aomori, Japan

11 Fukushima Medical University Hospital, Fukushima, Japan

12 Kansai Rosai Hospital, Hyogo, Japan

13 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan

14 Toyonaka Municipal Hospital, Toyonaka, Japan

15 Wakayama Medical University, Wakayama, Japan

16 Faculty of Medicine, Kagawa University, Kagawa, Japan

17 Osaka City General Hospital, Osaka, Japan

18 University of Tsukuba, Tsukuba, Japan

19 The University of Tokyo, Tokyo, Japan

Event

UEG Week Berlin 2025

Topics

Endoscopy Oesophagus

Submission format

Abstract

Session

Endoscopic resection in the upper GI tract

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Gut-brain chaos: Here’s how primary care can restore order

Christos D Lionis 1

1 University of Crete, Heraklion, Greece

Event

UEG Week Berlin 2025

Topics

Neurogastroenterology & Motility Paediatrics Standards & Guidelines Stomach & H. Pylori

Session

From guidelines to clinical practice: The gut-brain connection - PPIs and guideline application in clinical practice

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Designing non-pharmacological trials: Business as usual?

Laurie Keefer 1

1 Icahn School of Medicine, New York, United States of America

Event

UEG Week Berlin 2025

Topics

Mechanisms & Personalised Medicine Standards & Guidelines

Session

The art of making clinical research precise: Options for study design

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

For patients with Crohn’s disease (CD), endoscopic healing is an important long-term treatment goal per STRIDE-II consensus recommendations.¹ In this post hoc analysis, the relationships between endoscopic healing and long-term clinical outcomes were assessed in risankizumab (RZB)-treated patients with moderate to severe CD who previously failed tumor necrosis factor antagonist therapy from the phase 3 SEQUENCE trial.²

Aims & Methods

This analysis included RZB-treated patients who completed the week 48 visit in Part 1 of SEQUENCE (NCT04524611) and continued to receive RZB maintenance therapy during Part 2 of the trial. Part 2 is an ongoing open-label extension (OLE) wherein patients who received RZB induction and maintenance treatment during Part 1 could continue to receive RZB (subcutaneous 360mg every 8 weeks up to an additional 220 weeks). All patients in this post hoc analysis completed 100 weeks of RZB treatment (48 weeks in Part 1 and 52 weeks in Part 2). The proportion of patients who achieved week 100 (Part 2) clinical outcomes (including CD activity index [CDAI] response and remission, steroid-free CDAI clinical remission, and normalized fecal calprotectin [FCP] levels) were compared based on week 48 achievement of endoscopic response vs not, endoscopic remission vs not, and steroid-free endoscopic remission vs not (endpoint definitions in Table footnote), using chi-square testing. Patients with missing outcomes were imputed as nonresponders. Endoscopies were scored by a central reviewer. Long-term safety assessments for RZB have been reported elsewhere.³

Results

Of the 224 patients included in the analysis, 114 (50.9%), 80 (35.7%), and 80 (35.7%) patients achieved week 48 endoscopic response, endoscopic remission, and steroid-free endoscopic remission, respectively. A significantly greater proportion of patients who achieved week 48 endoscopic response also achieved week 100 CDAI remission and response, steroid-free CDAI clinical remission, and normalized FCP levels compared to patients who did not achieve week 48 endoscopic response (P≤.05 for all comparisons) (Table). Similar results were observed for patients who achieved week 48 endoscopic remission or steroid-free endoscopic remission (P≤.05 for all endpoints except for CDAI clinical response).

Clinical Outcomes at Week 100 (Week 52 of SEQUENCE OLE) n/N (%)	Week 48 Endoscopic response^a (Yes)	Week 48 Endoscopic response^a (No)	P value	Week 48 Endoscopic remission^b (Yes)	Week 48 Endoscopic remission^b (No)	P value	Week 48 Steroid-Free Endoscopic remission^c (Yes)	Week 48 Steroid-Free Endoscopic remission^c (No)	P value
CDAI clinical response^d CDAI clinical remission^e Steroid-free CDAI clinical remission^f Normalized FCP^g	80/114 (70.2) 77/114 (67.5) 77/114 (67.5) 67/114 (58.8)	61/110 (55.5) 57/110 (51.8) 57/110 (51.8) 49/110 (44.5)	.0226 .0164 .0164 .0332	57/80 (71.3) 55/80 (68.8) 55/80 (68.8) 54/80 (67.5)	84/144 (58.3) 79/144 (54.9) 79/144 (54.9) 62/144 (43.1)	.0551 .0422 .0422 .0005	57/80 (71.3) 55/80 (68.8) 55/80 (68.8) 54/80 (67.5)	84/144 (58.3) 79/144 (54.9) 79/144 (54.9) 62/144 (43.1)	.0551 .0422 .0422 .0005
Abbreviations: BL, baseline; CD, Crohn’s disease; CDAI, CD activity index; FCP, fecal calprotectin; OLE, open-label extension. ^aEndoscopic response: decrease in the SES-CD > 50% from induction BL (or for patients with isolated ileal disease and a BL SES-CD = 4, ≥ 2-point reduction from induction BL). ^bEndoscopic remission: SES-CD ≤ 4, ≥ 2-point reduction from BL, and no subscore >1 in any individual variable. ^cSteroid-free endoscopic remission: not receiving corticosteroids at the corresponding visit and in endoscopic remission. ^dCDAI clinical response: reduction of CDAI ≥ 100 points from induction BL. ^eCDAI clinical remission: CDAI < 150. ^fSteroid-free CDAI clinical remission: not receiving corticosteroids at the corresponding visit and in clinical remission. ^gNormalized FCP: ≤ 250 mcg/g. Bold font denotes a P value ≤ .05.

Conclusion

Results from this post hoc analysis of data from SEQUENCE demonstrated that achieving week 48 endoscopic outcomes was associated with sustained clinical improvements after 2 years of RZB treatment.

References

1. Turner D, et al. Gastroenterology. 2021 Apr;160(5):1570–83.
2. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213–23.
3. Peyrin-Biroulet L, et al. J Crohns Colitis. 2025 Jan 22;19(Supplement_1):i1405–7.

Disclosure

Disclosures
Vipul Jairath has received has received consulting/advisory board fees from AbbVie, Alimentiv Inc, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva, Topivert, Ventyx, and Vividion; and speaker’s fees from, AbbVie, Ferring, Galapagos, Janssen Pfizer Shire, Takeda, and Fresenius Kabi.
Christopher Ma has received consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Pendopharm, Pfizer, Prometheus Biosciences Inc., Roche, Sanofi, Takeda, Tillotts Pharma; speaker's fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Bristol Myers Squibb, Eli Lilly, Ferring, Fresenius Kabi, Janssen, Organon, Pendopharm, Pfizer, Sanofi, Takeda, Tillotts Pharma; royalties from Springer Publishing; research support from AbbVie, Ferring, Pfizer.
Peter Bossuyt received financial support for research from AbbVie, Amgen, Celltrion, Mylan, Pfizer, and Takeda; lecture fees from AbbVie, Celltrion, Janssen, Lilly, and Takeda; and advisory board fees from AbbVie, Arena Pharmaceuticals, BMS, Celltrion, Dr Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda, and Tetrameros.
Brian G Feagan has served as a consultant or received speaker’s fees from Abbott/AbbVie, ActoGeniX, Akros, Albireo Pharma, Amgen, AstraZeneca, Avaxia Biologics, Avir Pharma, Axcan, Baxter Healthcare, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring Pharmaceuticals, gIcare Pharma, Gilead, Given Imaging, GSK, Ironwood Pharmaceuticals, Janssen Biotech (Centocor), Johnson & Johnson/Janssen, Kyowa Hakko Kirin Co, Lexicon, Lilly, Lycera, Merck, Mesoblast, Millennium, Nektar, Nestlé, Novartis, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist Therapeutics, Receptos, Roche/Genentech, Salix Pharmaceuticals, Serono, Shire, Sigmoid Pharma, Synergy Pharmaceuticals, Takeda, Teva Pharmaceuticals, TiGenix, Tillotts, UCB, Vertex Pharmaceuticals, VHsquared, Warner Chilcott, Wyeth, Zealand Pharma, and Zyngenia, and has received research support from Abbott/AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Janssen Biotech (Centocor), Johnson & Johnson/Janssen, Millennium, Pfizer, Receptos, Roche/Genentech, Sanofi, Santarus, Tillotts, and UCB.
Namita Joshi, Nidhi Shukla, Kristina Kligys, Javier Zambrano, Toni Anschutz, and Brooke Kim are full-time employees/contractor of AbbVie and may own AbbVie stock or options.

Acknowledgments
AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the abstract. All authors had access to relevant data and participated in the drafting, review, and approval of this abstract. No honoraria or payments were made for authorship. AbbVie and authors thank all the trial investigators and the patients who participated in this clinical trial.
Medical writing support was provided by Stephanie Parsons, PhD, an employee of AbbVie. Editorial support was provided by Amy Kuang, an employee of AbbVie.

THE ASSOCIATION OF ENDOSCOPIC OUTCOMES WITH LONG-TERM CLINICAL IMPROVEMENTS IN RISANKIZUMAB-TREATED PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: POST HOC RESULTS FROM THE PHASE 3 SEQUENCE TRIAL

Vipul Jairath 1, Namita Joshi 2, Christopher Ma 3, Peter Bossuyt 4, Nidhi Shukla 2, Kristina Kligys 2, Javier Zambrano 2, Toni Anschutz 2, Brooke Kim 2, Brian G. Feagan 5

1 Western University, London, Canada|||Western University, London, Canada

2 AbbVie, North Chicago, United States

3 University of Calgary, Calgary, Canada|||University of Calgary, Calgary, Canada

4 Imelda General Hospital, Bonheiden, Belgium

5 Alimentiv Inc., London, Canada

Conference

UEG Week Berlin 2025

Topics

IBD

Submission format

Abstract

Session

Advanced therapy of Crohn's disease (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Not sure what you can access? Learn more about account types.

Introduction

Crohn's disease (CD) is a disabling and destructive disease. Early intervention associated with tight monitoring appear to the best way to achieve deep remission and to prevent disease progression. Whether anti-TNF (tumor necrosis factor) therapy can be interrupted in patients with early CD who have undergone a period of prolonged deep remission is unknown.

Aims & Methods

The primary objective was to evaluate the sustained deep remission rate one year after discontinuation of a 12-month course of adalimumab in adult patients with early CD who achieved deep remission at 12 months after treatment induction and who were already in clinical remission and biomarker remission at 6 months.
We carried out a multicentre prospective GETAID cohort study. All patients had early luminal CD less than 24 months since diagnosis, and were naïve to biologics. The primary study endpoint was percentage of patients with sustained deep remission one year after stopping a 12-months course of adalimumab (+/- 3 months) in adult patients with early-stage CD who achieved deep remission without therapeutic intervention (i.e. no surgery, no clinical flare-up, no introduction of CD-related treatment, no need for adalimumab optimization) AND who were already in clinical remission (CDAI < 150) and biomarker remission (CRP < 5 mg/L and fecal calprotectin < 250) at 6 months. A clinical flare-up was defined as a CDAI > 220 or an increase in CDAI between two subsequent visits > 70.

Results

A total of 171 patients received treatment with adalimumab between March 2015 and March 2019.
In this cohort, 39.2% (67/171) were active smokers. The median disease duration was 4 [2-9] months. CD location was ileal (42.7%, 73/171), colonic (12.3%, 21/171), and ileo colonic (44.4%, 76/171). Twenty-one patients (12.3%) had perianal disease. The majority of patients had an inflammatory phenotype (71.3%, 122/171). At inclusion, median CRP level was 9.0 [3.0-24.0] mg/L, and median fecal calprotectin was 440.5 [159.0-838.0] µg/g.
Overall, 38/171 (22.2%) of patients achieved deep remission after a 12-month course of adalimumab. From those who achieved deep remission, 7 patients did not discontinue adalimumab. In this study, 7/31 (22.6%) patients maintained their deep remission for one year after their treatment discontinuation (24 months from initiation of adalimumab). Among the whole cohort, only 4% (7/171) of patients were in deep remission off adalimumab at 2 years. Median time between adalimumab discontinuation and the first clinical relapse was 14 months. No predictive factor associated with loss of deep remission in the year following treatment discontinuation was identified. No serious adverse event was reported.

Conclusion

In this first prospective trial exploring withdrawal of advanced therapy in early CD, 22.6% achieved deep remission at one year with adalimumab; among them, about a quarter maintained deep remission at two years. These results demonstrate that anti-TNF therapy should not be discontinued, even in patients with early CD.

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Bénédicte Caron 1, Elodie Jeanbert 1, Florian Poullenot 2, Yoram Bouhnik 3, Lucine Vuitton 4, Catherine Reenaers 5, Stephane NANCEY 6, pierre Blanc 7, Xavier Roblin 8, Stéphanie Viennot 9, Jean-Louis Dupas 10, Anne Laure Pelletier 11, Arnaud Bourreille 12, Jacques Moreau 13, Jerome Filippi 14, Maria Nachury 15, Guillaume Bouguen 16, Marion Simon 17, Ludovic Caillo 18, Anthony Buisson 19, Laurianne Plastaras 20, Vered Abitbol 21, Alexandre Aubourg 22, Médina Boualit 23, David Laharie 24, Laurent Peyrin-Biroulet 25

1 Nancy University Hospital, Vandoeuvre les Nancy, France

2 Bordeaux University Hospital, Bordeaux, France

3 CHU Beaujon Dept. of IBD and Nutrition, Clichy, France

4 Besançon university hospital gastroenterology, Courbevoie, France

5 Assistants en formation gastro, réseau Ulg - CHU Sart Tilman, Assistants en formation gastro, réseau, Lantremange, Belgium

6 Lyon University Hospital, Pierre Benite, France

7 Hopital Saint Eloi, Montpellier, France

8 University of St. Etienne Dept. de Gastroenterologie, Saint Etienne, France

9 CHRU de Caen HGE 19è étage, Caen Cedex, France

10 CHU Nord Amiens, Amiens, France

11 Hopital Beaujon, Paris, France

12 Hopital Hotel Dieu Et Hme - Hge Aile Sud, Nantes Cedex 1, France

13 Centre Hospitalier Universitaire de Toulouse, Hopital Rangueil, Toulouse, France

14 Hopital de lAchet Dept. de Gastroenterlogie Dept. de Nutrition Oncologie, Nice Cedex 3, France

15 CHRU Lille, Courbevoie Cedex, France

16 CHU Pontchaillou, Rennes, France

17 Institut Mutualiste Montsouris, Paris, France

18 CHU DE NIMES, Nîmes, France

19 CHU Estaing Clermont-Ferrand, Clermont-ferrand, France

20 Chu Colmar, Colmar, France

21 Hopital Cochin Gastroentérologie AP-HP, Paris Cedex 14, France

22 Cabinet Medical, Chambray Les Tours, France

23 Ch Valenciennes, Valenciennes Cedex, France

24 CHU de Bordeaux Hopital Haut-Leveque Dept. de Gastroenterologie, Pessac cedex, France

25 Inserm U1256, Nancy University Hospital, Vandoeuvre-les-Nancy, France

Event

UEG Week Berlin 2025

Topics

IBD Mechanisms & Personalised Medicine

Submission format

Abstract

Session

Clinical management of IBD

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Risankizumab is an interleukin-23 inhibitor approved for the treatment of Crohn’s disease (CD). Its efficacy and safety have recently been demonstrated in trial-setting but there is yet limited evidence of its real-world effectiveness, especially on the middle- and long-term.

Aims & Methods

Using prospective data from the Dutch Initiative on Crohn and Colitis (ICC) Registry, we aimed to evaluate the effectiveness and adverse events of risankizumab in patients with difficult-to-treat CD, defined as the failure of advanced therapies with at least two different mechanisms of action¹. The primary endpoint was corticosteroid-free (CSF) clinical remission at week (W) 24. CSF clinical remission was defined as Harvey Bradshaw Index (HBI) ≤ 4 and no use of systemic corticosteroids at the time of the visit. As secondary outcomes, we examined clinical remission, biochemical remission (faecal calprotectin (FC) level ≤ 250μg/g) and combined clinical and biochemical remission at W24. Furthermore, remission rates between patients without history of bowel resection (i.e. surgery-naïve) and with bowel resection (i.e. surgery-experienced) at W24, drug survival and adverse events were assessed. Patients were included in the analysis if they received at least one intravenous dose of risankizumab before the 28^th of February 2025. Patients without available remission data at W24 and who remained on treatment were excluded from the W24 analysis population. Patients who discontinued treatment before W24 due to non-response, adverse events or loss to follow-up were considered non-responders.

Results

Eighty-five patients were included in the current analysis; 56 (65.9%) were female. Patients had a median disease duration of 16.0 years (IQR 14.0). Surgery history was available for 83 patients; 33 (39.8%) patients did not undergo surgery, while 50 (60.2%) were considered as surgery-experienced. At baseline, HBI was available for 72 patients; the median HBI was 6 (IQR 5); 24 (33.3%) patients had an HBI ≤ 4. Biochemical data were available for 19 (79.2%) patients in clinical remission: only one (5.3%) was in biochemical remission. At W24, HBI was available for 62 patients; 34 (54.8%) patients were in CSF clinical remission. Independent of CSF status, 62.9% (39/62) of the patients were in clinical remission. FC levels at W24 were available for 55 patients; 17 (30.9%) patients were in biochemical remission. Remission rates were not influenced by surgery history (Table 1). Over time, 16.5% (14/85) patients stopped risankizumab, after a median treatment duration of 182 days (IQR 188). Three (21.4%) patients discontinued risankizumab before W12, three (21.4%) between W12 and W24, and eight (57.2%) between W24 and W52. Reasons for discontinuation were non-response (42.9%), loss of response (42.9%) and adverse events (14.2%). A total of 83 adverse events were reported in 51 patients. Most common adverse events included respiratory infections (13.2%), skin problems (10.8%) and herpes zoster infections (8.4%). No hospitalisation or death were reported.

Table 1. Overview of the remission rates at W24 between surgery-naïve and surgery-experienced patients
	CSF clinical remission	Clinical remission	Biochemical remission	Combined remission
Total	34/62 54.8%	39/62 62.9%	17/55 30.9%	17/43 39.5%
Surgery-naïve	15/23 65.2%	17/23 73.9%	6/21 28.6%	6/16 37.5%
Surgery-experienced	19/37 51.3%	22/37 59.5%	11/32 34.8%	11/24 45.8%

Conclusion

This prospective real-world study demonstrates the clinical effectiveness and the favourable safety profile of risankizumab at W24 in a difficult-to-treat Crohn’s disease population, including a high proportion of patients with bowel resection.

References

1. Parigi TL, D'Amico F, Abreu MT, Dignass A, Dotan I, Magro F, Griffiths AM, Jairath V, Iacucci M, Mantzaris GJ, O'Morain C, Reinisch W, Sachar DB, Turner D, Yamamoto T, Rubin DT, Peyrin-Biroulet L, Ghosh S, Danese S. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):853-859. doi: 10.1016/S2468-1253(23)00154-1. Epub 2023 Jul 6. PMID: 37423233.

Disclosure

LMMV - none FDMvS - adviser and/or speaker for Takeda, Galapagos, Dr. Falk, Lilly, and Janssen-Cilag; received an unrestricted grant from Takeda MRN - none ACdV - advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos; research grants from Takeda, Janssen, and Pfizer AEvdMDJ - speaker fee from AbbVie, Alfasigma, Ferring, Janssen Pharmaceuticals, Takeda, Tramedico, and Vedanta; grants from Norgine, Cablon, Alfasigma, and ZonMW MCV - speaker fees from Janssen-Cilag, Galapagos, and Ferring B.V. WAvD - none WSN - none TER - none RLW - speaker fee from Abbvie, Ferring, and Pfizer BJ - none AGLB - none PV - speaker fee from Takeda, Abbvie, Janssen, Alfa Sigma, Lilly, and BMS BO - advisory boards of Takeda, BMS, Galapagos, Janssen, AbbVie, BMS, and Ferring; grants from Takeda, Pfizer, Galapagos, Ferring, Celltrion, BMS, and AbbVie ML - consultancy/lecture fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Galapagos, Janssen-Cilag, Johnson & Johnson, Medtronic, Pfizer, Takeda, and Tillotts Pharma; grants from Alfasigma, the Netherlands Federation of University Medical Centres, TKI, and ZonMW JELS - none LAAPD - served on advisory boards as a speaker for Abbvie, Alfasigma, Janssen, and Pfizer; independent research funding from Pfizer HHF - none MJP - speaker fee from BMS, Janssen Cilag, and Takeda; non-restricted research grants from Horizon 2020, ZONMW (Dutch national research fund), MLDS, Takeda, Johnson and Johnson, Abbvie, and Galapagos MD - speaking fee from Bristol Meyers Squibb, Takeda, Galapagos, Janssen, and Dr. Falk; advisory board fees from Abbvie, Bristol Meyers Squibb, Celltrion, Galapagos/Alfasigma, Janssen, Takeda; grant/research support from Pfizer, Bristol Meyers Squibb, Galapagos Alfasigma, and Janssen ZM - speaker fee from Friso – Friesland Campina, Galapagos, Eli Lilly, and Takeda (paid to host institution); ; advisory board fees from Johnson & Johnson, Eli Lilly, Pfizer (paid to host institution); grants from ZonMw, Niels Stensen Fellowship, MLDS, Top consortium for Knowledge and Innovation (TKI), and Galapagos

EFFECTIVENESS OF RISANKIZUMAB IN DIFFICULT-TO-TREAT CROHN'S DISEASE - PROSPECTIVE REAL-WORLD EVIDENCE FROM THE INITIATIVE ON CROHN AND COLITIS REGISTRY

Loriane Verleye 1, Fiona Van Schaik 2, Myrthe Naber 3, Annemarie de Vries 4, Andrea E. Van Der Meulen - De Jong 5, Marijn C. Visschedijk 6, Willemijn Van Dop 7, Safioen Nabibaks 4, Tessa E.H. Römkens 8, Rachel West 9, Bindia Jharap 10, Alexander Bodelier 11, Philip Voorneveld 5, Bas Oldenburg 2, Mark Lowenberg 12, Jael Smid 6, Lauranne Derikx 4, Herma H. Fidder 2, Marieke Pierik 13, Marjolijn Duijvestein 7, Zlatan Mujagic 13

1 Maastricht University Medical Center+, Maastricht, Netherlands|||Radboudumc, Nijmegen, Netherlands

2 University Medical Center Utrecht, Utrecht, Netherlands

3 University Medical Center Utrecht, Utrecht, Netherlands|||Amsterdam University Medical Center, Amsterdam, Netherlands

4 Erasmus MC, Rotterdam, Netherlands

5 Leiden University Medical Center, Leiden, Netherlands

6 University Medical Center Groningen, Groningen, Netherlands

7 Radboudumc, Nijmegen, Netherlands

8 Jeroen Bosch Hospital, Den Bosch, Netherlands

9 Sint Franciscus Gasthuis, Rotterdam, Netherlands

10 Meander Medical Center, Amersfoort, Netherlands

11 Amphia Hospital, Breda, Netherlands

12 Amsterdam University Medical Center, Amsterdam, Netherlands

13 Maastricht University Medical Center+, Maastricht, Netherlands

Conference

UEG Week Berlin 2025

Topics

IBD

Submission format

Abstract

Session

Crohn's disease: Postoperative course and outcomes (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Week 2025: Relive the Highlights

Most popular content

Rate for better recommendations!